We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Allergy Therapeutics Plc | LSE:AGY | London | Ordinary Share | GB00B02LCQ05 | ORD 0.1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.025 | -0.86% | 2.875 | 2.75 | 3.00 | 3.10 | 2.875 | 2.95 | 759,943 | 11:42:05 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 59.59M | -43.07M | -0.0090 | -3.19 | 136.8M |
From May 2019 to May 2024
TIDMAGY
RNS Number : 8466B
Allergy Therapeutics PLC
12 January 2015
12 January 2015
Allergy Therapeutics plc
("Allergy Therapeutics"or the 'Company")
Trading Update
Allergy Therapeutics, the fully integrated specialty pharmaceutical company specialising in allergy vaccines, will announce its unaudited interim results for the 6 months ended 31 December 2014 on 2 March 2015.
The Company expects to report revenue growth of 11% for the period at constant currency, with first half revenues of approximately GBP30.2m (H1 2014: GBP27.2m). This double digit sales growth has been driven primarily by the Company's improving trading performance as it continues to increase its market share in all of its main markets.
First half reported revenues are expected to be approximately GBP28.2m (H1 2014: GBP27.2m), representing growth of 4% taking into account currency impacts; the negative impact from the weakening Euro being GBP2.0m.
Manuel Llobet, Chief Executive Officer, said:
"Despite flat markets, we have been able to grow double digit at constant currency by increasing our market share, particularly in Germany and the Netherlands, thanks to our winning range of short course aluminium free allergy vaccines."
Allergy Therapeutics +44 (0) 1903 845 820 Manuel Llobet, Chief Executive Officer Ian Postlethwaite, Finance Director Panmure Gordon +44 (0) 20 7886 2500 Freddy Crossley / Duncan Monteith, Corporate Finance Tom Salvesen, Corporate Broking FTI Consulting +44 (0) 20 3727 1000 Simon Conway Victoria Foster Mitchell
Note to editors
About Allergy Therapeutics
Allergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination. It has a growing business achieving revenue in the last financial year of GBP42 million mainly in Europe through its own sales and marketing infrastructure and further afield through distributors.
This information is provided by RNS
The company news service from the London Stock Exchange
END
TSTLIFVILEIFLIE
1 Year Allergy Therapeutics Chart |
1 Month Allergy Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
